See the DrugPatentWatch profile for Voquezna
Voquezna is available in Mexico. It is a combination therapy approved for the treatment of Helicobacter pylori (H. pylori) infection in adults [1].
What is Voquezna approved to treat?
Voquezna is approved for the treatment of H. pylori infection in adult patients [1].
What are the components of Voquezna?
Voquezna is a prescription medication containing two active ingredients: amoxicillin and valbenanase [1]. It is administered as a sublingual (under the tongue) tablet [1].
How does Voquezna work?
Valbenanase works by inhibiting bacterial protein synthesis, and amoxicillin is a penicillin-class antibacterial that inhibits bacterial cell wall synthesis [1]. Together, they are effective against H. pylori [1].
When was Voquezna approved in Mexico?
Information on the specific approval date of Voquezna in Mexico is not provided. However, it is available there [1].
Who manufactures Voquezna?
Cosette Pharmaceuticals, Inc. manufactures Voquezna [1].
What is the dosage for Voquezna?
The typical dosage for Voquezna is one 42.3 mg amoxicillin and 34.2 mg valbenanase sublingual tablet, taken twice daily for 14 days [1]. Specific instructions should always be followed as prescribed by a healthcare professional.
Are there alternatives to Voquezna for H. pylori treatment?
Other treatment regimens for H. pylori infection exist, typically involving combinations of antibiotics and acid-reducing medications [2]. Treatment protocols can vary based on local resistance patterns and patient history [2]. For example, triple therapy often includes a proton pump inhibitor (PPI) with clarithromycin and amoxicillin or metronidazole [2]. Quadruple therapy may involve a PPI, bismuth, and two antibiotics [2].
What are the potential side effects of Voquezna?
Common side effects reported with Voquezna include altered taste, diarrhea, nausea, and headache [1]. More serious side effects are possible, and patients should report any adverse reactions to their doctor [1].
What are the risks associated with H. pylori treatment?
Risks associated with H. pylori treatment can include allergic reactions to antibiotics, the development of antibiotic resistance, and gastrointestinal side effects [1][2]. It is crucial to complete the full course of treatment as prescribed to maximize effectiveness and minimize resistance [1][2].
Where can I find more information about Voquezna?
Further information about Voquezna and its use in treating H. pylori infections can be found through healthcare providers or by consulting official drug information resources. DrugPatentWatch.com provides information on drug patents and exclusivity [3].
---
Sources:
[1] Cosette Pharmaceuticals, Inc. VOQUEZNA (amoxicillin and valbenanase) sublingual film. October 2023.
[2] National Institute of Diabetes and Digestive and Kidney Diseases. H. pylori and Ulcers.
[3] DrugPatentWatch.com.